Annual report 2016 Active Biotech AB (publ)


Annual report 2016 Active Biotech AB (publ)

Active Biotech’s annual report for 2016 is now available on the

The annual report will only be digitally distributed.

Lund, 18 may 2017

Active Biotech AB (publ)

Tomas Leanderson

Executive director

For further information, please contact:

Hans Kolam, CFO

Tel 046 192044

If Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company focused on the development of drugs for the treatment of neurodegenerative/inflammatory diseases and cancer. Laquinimod, a substance in tablet form with unique immunomodulatory properties, is in phase 2 trials for the treatment of primärprogressiv multiple sclerosis and Huntington’s disease. Anyara, a immunonkologisk substance, has undergone clinical phase 1-2/3 in patients with pancreatic, lung or renal cancer. Furthermore, the conducted commercial activities for the projects tasquinimod, paquinimod and SILC. For further information please visit

Active Biotech AB

Box 724, 220 07 Lund, Sweden

Tel 046-19 20 00

This information is such information that Active Biotech AB is obligated to publish under the Swedish securities market act. The information was submitted for publication 18 may 2017, there is a 14.30.

Annual report 2016 Active Biotech AB (publ)

Like this post? Please share to your friends:
Leave a Reply